BMS 247550 to Treat Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

January 31, 2009

Study Completion Date

June 30, 2012

Conditions
Renal Cell Carcinoma
Interventions
DRUG

BMS-247550

One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m\^2/day for a total per cycle dose of 30 mg/m\^2

DRUG

Ranitidine

50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)

DRUG

Diphenhydramine

50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00030992 - BMS 247550 to Treat Kidney Cancer | Biotech Hunter | Biotech Hunter